REGENERON PHARMACEUTICALS, INC. Operating Income Loss

Quick Answer

REGENERON PHARMACEUTICALS, INC. reported Operating Income Loss of $3.58 billion for the year ending 2025.

  • REGENERON PHARMACEUTICALS, INC. showed a decrease of -10.3% in Operating Income Loss from 2024 to 2025.
  • This data is from REGENERON PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on February 4, 2026.
  • XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 18 years of available data (2008 to 2025), REGENERON PHARMACEUTICALS, INC.'s Operating Income Loss has grown by 4,248.3%.
  • Historical annual values: Fiscal year 2025: $3.58 billion | Fiscal year 2024: $3.99 billion | Fiscal year 2023: $4.05 billion | Fiscal year 2022: $4.74 billion | Fiscal year 2021: $8.95 billion | Fiscal year 2020: $3.58 billion | Fiscal year 2019: $2.21 billion | Fiscal year 2018: $2.53 billion | Fiscal year 2017: $2.08 billion | Fiscal year 2016: $1.33 billion | Fiscal year 2015: $1.25 billion | Fiscal year 2014: $823.92 million | Fiscal year 2013: $743.05 million | Fiscal year 2012: $457.71 million | Fiscal year 2011: -$205.16 million | Fiscal year 2010: -$97.47 million | Fiscal year 2009: -$74.10 million | Fiscal year 2008: -$86.25 million.
  • Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: